Data quality issues emerge from multiple failure points from development practices to production life cycle, each compounding ...

The article, "Durability of next-generation self-replicating RNA vaccine RBI-4000: a Phase 1, randomized open label clinical trial," includes long term immunogenicity data from the company's rabies ...

Databases are a lot like programming languages: there’s a great variety to choose from, they have wildly different programming and query interfaces, and there’s a wide gap in available features. And ...

ZUG, Switzerland--(BUSINESS WIRE)--Galderma today announced that it will present new data from the ARCADIA and OLYMPIA clinical trial programs investigating nemolizumab in atopic dermatitis and ...

Results further validate PlaCCine as a novel vaccine platform with potential applications in COVID-19 and other infectious diseases with epidemic implications “It is very encouraging to see strong ...

MILPITAS, Calif.--(BUSINESS WIRE)--VDURA, a global leader in AI and HPC data infrastructure and management solutions, will highlight its next generation data platform at the 18th annual Energy High ...

Michael Wang, MD, highlights several notable abstracts from ASH 2025 that collectively underscore continued progress in ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. Vivek Yadav, an engineering manager from ...

As I argued in my 2022 article, “Beyond 'X Number Served,'” nonprofits and donors should expand our thinking beyond the number of beneficiaries we reach. We should hold ourselves accountable for two ...

Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED) - 70% of patients treated with ...

- Potential first-in-class gene editing approach designed for dystrophin gene correction leading the body to produce a functional dystrophin protein applicable for majority of DMD patients (up to ~60% ...